Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

  • participants needed
  • sponsor
    Navitor Pharmaceuticals, Inc.
Updated on 8 September 2023


This study will evaluate the efficacy and safety of NV-5138 in adults with TRD


The is a multicenter, randomized, double-blind, flexible- dose, placebo-controlled, parallel design of adjunctive NV-5138 in adults with TRD.

Condition Treatment Resistant Depression
Treatment Matched placebo, NV-5138
Clinical Study IdentifierNCT05066672
SponsorNavitor Pharmaceuticals, Inc.
Last Modified on8 September 2023

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note